Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D09OYA
|
||||
Former ID |
DIB018821
|
||||
Drug Name |
alpha-methyl-5-HT
|
||||
Synonyms |
alpha-Me-5-HT; alpha-methylserotonin
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [538941] | ||
Structure |
Download2D MOL |
||||
Formula |
C11H14N2O
|
||||
InChI |
InChI=1S/C11H14N2O/c1-7(12)4-8-6-13-11-3-2-9(14)5-10(8)11/h2-3,5-7,13-14H,4,12H2,1H3
|
||||
InChIKey |
LYPCGXKCQDYTFV-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
7402877, 7978666, 8151425, 14797321, 26751772, 29221287, 46530747, 47217002, 47365424, 47440491, 47515544, 47662519, 47885616, 48035362, 50104459, 57321141, 77795200, 85209844, 90341561, 103182897, 103926819, 104299625, 124750028, 124880621, 124880622, 128560036, 134341330, 135649924, 137005041, 140189870, 143298771, 163240508, 164780431, 170539560, 179236039, 216242915, 225119218, 226725872
|
||||
Target and Pathway | |||||
Target(s) | 5-hydroxytryptamine 1E receptor | Target Info | Agonist | [526943] | |
5-hydroxytryptamine 1F receptor | Target Info | Agonist | [534001] | ||
5-hydroxytryptamine 4 receptor | Target Info | Agonist | [534429] | ||
5-hydroxytryptamine 2C receptor | Target Info | Agonist | [525477] | ||
5-hydroxytryptamine 2B receptor | Target Info | Agonist | [527238] | ||
5-hydroxytryptamine 6 receptor | Target Info | Agonist | [534734] | ||
5-hydroxytryptamine 2A receptor | Target Info | Agonist | [525890] | ||
5-hydroxytryptamine 1D receptor | Target Info | Agonist | [534292] | ||
KEGG Pathway | cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Serotonergic synapsehsa04024:cAMP signaling pathway | |||||
Serotonergic synapsehsa04020:Calcium signaling pathway | |||||
Gap junction | |||||
Serotonergic synapse | |||||
Inflammatory mediator regulation of TRP channelshsa04020:Calcium signaling pathway | |||||
Inflammatory mediator regulation of TRP channelshsa04024:cAMP signaling pathway | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
5HT1 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
5HT4 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathwayP04374:5HT2 type receptor mediated signaling pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
5HT1 type receptor mediated signaling pathway | |||||
WikiPathways | Serotonin HTR1 Group and FOS Pathway | ||||
Monoamine GPCRs | |||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP722:Serotonin HTR1 Group and FOS Pathway | |||||
GPCR downstream signaling | |||||
GPCRs, OtherWP734:Serotonin Receptor 4/6/7 and NR3C Signaling | |||||
GPCR downstream signalingWP732:Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
GPCR downstream signalingWP734:Serotonin Receptor 4/6/7 and NR3C Signaling | |||||
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling | |||||
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | |||||
SIDS Susceptibility Pathways | |||||
GPCRs, OtherWP722:Serotonin HTR1 Group and FOS Pathway | |||||
References | |||||
Ref 525477 | High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT2A and 5-HT2C receptors: evidence favoring the ternary complex and two-state models of agonist action. J Neurochem. 1999 May;72(5):2127-34. | ||||
Ref 525890 | Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol. 2000 Nov;58(5):877-86. | ||||
Ref 526943 | Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor. Eur J Pharmacol. 2004 Jan 26;484(2-3):127-39. | ||||
Ref 527238 | The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo. Br J Pharmacol. 2004 Nov;143(5):549-60. Epub 2004 Oct 4. | ||||
Ref 534001 | Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):408-12. | ||||
Ref 534292 | Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan. Mol Pharmacol. 1996 Dec;50(6):1567-80. | ||||
Ref 534429 | [3H]RS 57639, a high affinity, selective 5-HT4 receptor partial agonist, specifically labels guinea-pig striatal and rat cloned (5-HT4S and 5-HT4L) receptors. Neuropharmacology. 1997 Apr-May;36(4-5):671-9. | ||||
Ref 534734 | Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.